The Right Direction for your Research Needs

separator

When the right response from a research participant can make the difference for your end client, the ability to gather accurate insights from trusted respondents is critical for any companies’ decision-making process. Here’s how Guidepoint helps our clients ascertain the right information every time:     Through the unmatched speed of our offerings, we help […]

Read More

Guidepoint Helps Consultants Best Serve Their Clients

separator

One of the biggest challenges in an information-based economy is finding the right information when you need it. Whether it’s getting up to speed quickly on a project, or gaining insight on competitive landscapes, here’s how we help consulting firms serve their clients more efficiently.     Through our unmatched offerings, we give consultants the […]

Read More

Wright Medical: The Beginning of a Turnaround?

separator

by Kenny Dolgin, Healthcare Analyst, Data Insights, Guidepoint Wright Medical Group N.V. (NASDAQ: WMGI) is a mid-cap medical device company that competes in the orthopedics market with a focus on the upper extremities, lower extremities and biologics product areas. Key products include their INFINITY total ankle system, SIMPLICITI shoulder system, and AUGMENT bone graft. According […]

Read More

Will the Sinuva launch propel XENT to a higher level of growth?

separator

by Kenny Dolgin, Healthcare Analyst, Data Insights, Guidepoint Intersect ENT Inc. (NASDAQ: XENT) is a small-cap medical device company which competes in the ear, nose and throat (ENT) market. Since January 2017, Intersect’s stock price has grown 181% making it one of the top performing stocks in the medical device space over that period.   […]

Read More

Nevro – Spinal Cord Stimulation Market at a Crossroads

separator

by Ken Wahl, VP Business Development, Data Insights, Guidepoint Nevro Corp. (NYSE: NVRO) is a key player in the spinal cord stimulation (SCS) market. Since FDA approval of the Senza system in 2015, Nevro has taken ~15% market share from well-established market leaders Abbott/St. Jude, Medtronic and Boston Scientific. The U.S. SCS market was an […]

Read More

Can Abiomed sustain its impressive sales growth in FY 2019?

separator

by Kenny Dolgin, Data Insights, Guidepoint Abiomed, Inc. (NYSE: ABMD) is a leader in the percutaneous heart pump device market, having launched its first Impella device in 2008 and have since released four iterations with varying flow rates. From May 2013 to May 2018, Abiomed’s stock price delivered a 5-year CAGR of 75%, making it […]

Read More

Can Edwards Lifesciences Fend Off Medtronic?

separator

by Kenny Dolgin, Data Insights, Guidepoint Edwards Lifesciences Corp. (NYSE: EW) is a leader in the approximately $3 billion transcatheter heart valve (THV) market, having launched their first SAPIEN valve in the U.S. in 2011 and now having released their third generation valve. From 2013 to 2017, Edwards’ stock price delivered a 5-year CAGR of […]

Read More

Is Q4 2017 Another Inflection Point For Penumbra?

separator

by Kenny Dolgin, Data Insights, Guidepoint Penumbra Inc. (NYSE: PEN) is a key player in the treatment for ischemic stroke, having received FDA approval for the first aspiration-based thrombectomy system in 2007 and having since launched five new generations of the device. In the U.S., Penumbra caters to a total addressable market of approximately $1.5 […]

Read More

Consultants Call on Guidepoint

separator

Guidepoint works with over 1,000 clients, including 9 of the top 10 global consulting firms.   Our network is made up of over 440,000 Advisors covering all sectors, regions and relevant industries. These Advisors are C-Suite Decision Makers, Customers, Suppliers, Operations, Procurement, etc.   Our dedicated global servicing teams provide strategic recruiting resources and can […]

Read More

Hemophilia Treatment:
A Market Poised for Revolutionary Changes in 2018

separator

by Ken Wahl, Data Insights, Guidepoint Shire Plc’s (NYSE: SHPG) US hemophilia sales have faced much competition in recent years. In particular, their leading hemophilia A treatment Advate, an older, shorter-acting recombinant factor VIII, is facing many new US market entrants with longer half-lives. However, the global hemophilia portfolio including Adynovate has managed to maintain […]

Read More